flag Eng flag 简体中文 flag العربيّة

Safety Data

Drug Safety

Comprehensive Safety Information

Taj Pharma is committed to ensuring the safety and well-being of patients using Mefloquine Hydrochloride Tablets. Our comprehensive pharmacovigilance program monitors and evaluates safety data to maintain the highest standards of patient care.

This section provides detailed safety information including adverse reactions, special precautions, and guidelines for reporting safety concerns. Healthcare professionals are encouraged to report any suspected adverse reactions.

Continuous Monitoring

Ongoing safety surveillance and adverse event monitoring worldwide.

Adverse Event Reporting

Comprehensive system for collecting and analyzing safety reports.

Risk Management

Proactive risk assessment and mitigation strategies.

Safety Monitoring
Shape
Adverse Reactions

Safety Profile & Side Effects

Frequency of Adverse Reactions

Very Common (≥10%)

Gastrointestinal Disorders
  • Nausea
  • Vomiting
  • Diarrhea
  • Abdominal pain
Nervous System Disorders
  • Dizziness
  • Headache
  • Vertigo
  • Balance disorders
Psychiatric Disorders
  • Sleep disturbances
  • Abnormal dreams
  • Insomnia

Common (1-10%)

Psychiatric Disorders
  • Anxiety
  • Depression
  • Irritability
  • Mood changes
General Disorders
  • Fatigue
  • Weakness
  • Fever
  • Malaise
Skin and Subcutaneous Tissue Disorders
  • Pruritus
  • Rash
  • Urticaria

Uncommon (0.1-1%)

Cardiac Disorders
  • Palpitations
  • Tachycardia
  • QT interval prolongation
Hepatobiliary Disorders
  • Elevated liver enzymes
  • Hepatitis

Rare (<0.1%)

Serious Adverse Reactions
  • Seizures
  • Psychotic reactions
  • Severe depression
  • Suicidal ideation
  • Cardiac arrhythmias
  • Severe skin reactions (SJS, TEN)
  • Anaphylaxis
Special Populations

Safety Considerations for Specific Groups

Pregnancy

Pregnancy

First Trimester: Contraindicated

Second/Third Trimester: Use only if benefit outweighs risk

Key Concerns:

  • Potential fetal toxicity
  • Limited safety data
  • Alternative treatments preferred
Pediatrics

Pediatrics

Age >6 months, weight >5kg: Can be used

Dosing: Weight-based (5 mg/kg prophylaxis, 25 mg/kg treatment)

Key Concerns:

  • Increased seizure risk
  • Neuropsychiatric effects
  • Careful monitoring required
Elderly

Elderly (≥65 years)

Considerations: Use with caution

Key Concerns:

  • Renal impairment
  • Hepatic impairment
  • Cardiac comorbidities
  • Increased adverse reaction risk
Safety Interactions

Drug-Drug Interaction Safety

Absolute Contraindications - Do Not Combine

Chloroquine

Risk: Increased risk of convulsions and seizures

Mechanism: Additive neurotoxicity

Recommendation: Avoid concurrent use

Quinidine, Quinine

Risk: Increased cardiac toxicity, arrhythmias

Mechanism: Additive QT prolongation

Recommendation: Avoid concurrent use

Use with Extreme Caution - Close Monitoring Required

Anti-arrhythmic Drugs

Examples: Amiodarone, sotalol, dofetilide

Risk: Severe QT prolongation, torsades de pointes

Recommendation: Avoid if possible, ECG monitoring if necessary

Antipsychotics

Examples: Haloperidol, risperidone, quetiapine

Risk: Increased neuropsychiatric effects

Recommendation: Use with caution, monitor mental status

Antidepressants

Examples: SSRIs, TCAs, MAOIs

Risk: Increased depression risk, serotonin syndrome

Recommendation: Use with caution, monitor mood

Use with Caution - Monitor Closely

Antiepileptics

Examples: Carbamazepine, phenytoin, valproic acid

Risk: Reduced mefloquine efficacy

Recommendation: Monitor therapeutic response

Antibiotics

Examples: Macrolides, fluoroquinolones

Risk: Increased QT prolongation risk

Recommendation: Monitor ECG if risk factors present

Pharmacovigilance

Adverse Event Reporting

Healthcare Professionals: Please report any suspected adverse reactions to Mefloquine to help improve patient safety.

How to Report Adverse Events

Telephone Reporting

Pharmacovigilance Hotline: +91 84484 44095

Available: 24/7 for serious adverse events

Business Hours: 9:00 AM - 6:00 PM IST for non-serious events

Email Reporting

Pharmacovigilance Email: pv@tajpharma.com

Response Time: Within 24 hours

Format: Include patient details, drug information, and adverse event description

Online Reporting

Web Portal: www.tajpharma.com/pv-report

Features: Secure reporting, tracking, and follow-up

Registration: Healthcare professional registration required

Information Required for Reporting

Patient Information

  • Age and gender
  • Relevant medical history
  • Concomitant medications
  • Pregnancy status (if applicable)

Drug Information

  • Mefloquine dose and frequency
  • Start date of therapy
  • Batch/lot number (if available)
  • Indication for use

Adverse Event Details

  • Description of reaction
  • Date of onset and duration
  • Severity assessment
  • Outcome of the event
  • Actions taken

Reporter Information

  • Name and qualification
  • Contact information
  • Relationship to patient
Reporting Timeline: Serious adverse events should be reported within 24 hours of occurrence. Non-serious events should be reported within 7 days.